These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
537 related articles for article (PubMed ID: 19680292)
21. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Kotsakis A; Georgoulias V Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711 [TBL] [Abstract][Full Text] [Related]
22. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221 [TBL] [Abstract][Full Text] [Related]
23. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541 [TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825 [TBL] [Abstract][Full Text] [Related]
25. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Hirsch FR; Varella-Garcia M; Cappuzzo F Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294 [TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Modjtahedi H; Essapen S Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350 [TBL] [Abstract][Full Text] [Related]
27. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Kancha RK; von Bubnoff N; Peschel C; Duyster J Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750 [TBL] [Abstract][Full Text] [Related]
28. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Bunn PA; Thatcher N Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773 [TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816 [TBL] [Abstract][Full Text] [Related]
30. Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer. Pennell NA Clin Lung Cancer; 2011 Nov; 12(6):350-9. PubMed ID: 21723791 [TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor mutations in lung cancer. Sharma SV; Bell DW; Settleman J; Haber DA Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210 [TBL] [Abstract][Full Text] [Related]
32. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350 [TBL] [Abstract][Full Text] [Related]
33. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740 [TBL] [Abstract][Full Text] [Related]
34. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Liu W; Wu X; Zhang W; Montenegro RC; Fackenthal DL; Spitz JA; Huff LM; Innocenti F; Das S; Cook EH; Cox NJ; Bates SE; Ratain MJ Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6788-95. PubMed ID: 18006781 [TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662 [TBL] [Abstract][Full Text] [Related]
36. Factors predicting response to EGFR tyrosine kinase inhibitors. Engelman JA; Jänne PA Semin Respir Crit Care Med; 2005 Jun; 26(3):314-22. PubMed ID: 16052433 [TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Pennell NA; Lynch TJ Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226 [TBL] [Abstract][Full Text] [Related]
38. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. Sequist LV; Bell DW; Lynch TJ; Haber DA J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067 [TBL] [Abstract][Full Text] [Related]
39. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Toschi L; Cappuzzo F Oncologist; 2007 Feb; 12(2):211-20. PubMed ID: 17296817 [TBL] [Abstract][Full Text] [Related]
40. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Zhang J; Jia J; Zhu F; Ma X; Han B; Wei X; Tan C; Jiang Y; Chen Y Mol Biosyst; 2012 Oct; 8(10):2645-56. PubMed ID: 22833077 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]